During these last days of summer, we here at Disruptive Women are reflecting on posts from when we first launched—it’s fascinating to see how far we’ve come and where we still have to go—to push—to Disrupt. After all, a woman’s work is never done. We originally published this post on September 25, 2008.
Shortly after the passage of the Genetic Information Nondiscrimination Act, in the 110th Congress, a reporter asked me why I thought the bill was so important. I pondered the question briefly and replied, perhaps in a way she was not expecting, that I felt we now were poised with an informed congress who better understands the potential importance of an individual’s genome information.
To take that thought one step further, I believe this landmark legislation and the thirteen years which led up to its passage have provided our country and our citizens with a renewed energy to guide our congress once again to build the next story – providing our citizens with the potential for better and more personalized healthcare.
Earlier this month, we once again saw the topic of genomics and medicine brought to the halls of the 111th Congress with Representative Kennedy’s introduction of the Genomics and Personalized Medicine Act of 2008 (H.R.6498). The bill originally proposed by Senator Obama in the 110th Congress once again brings new hope for patients and signals that scientific innovation is important in our country.
As a scientist who is passionate about the ability to use the knowledge of the genome to improve human health through better disease diagnosis and treatment, this legislation let the debate begin.
I am anxious to see once again how science and technology can disrupt the future of “health care as usual.”
I look forward to sharing our progress in this field of personalized medicine and sharing my experiences in both the pharmaceutical industry during my time at Pfizer and in my new role as the CSO at Helicos, an innovative single molecule DNA sequencing company poised to play a key role in our path to the future.